Business
RepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints
RepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints\nPR Newswire\nVANCOUVER, March 14, 2017\n\n\n\nFive-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy\n\n\n\nVANCOUVER, March 14, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (\"RepliCel\" or the \"Company\"), a clinical stage regenerative medicine company developing unique biologic products for pattern baldness and thinning hair, aging and sun-damaged skin, and chronic tendon degeneration, today announced the successful completion of its first-in-human clinical study of the Company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness). \n\nThe Company reports the trial succesfully met its endpoints and sets the stage for next steps in the  ongoing research and development of its product, RCH-01, for the treatment of male and female androgenetic alopecia. \"As we march toward commercialization of this product based on this first-in-human data, our aim is to revolutionize the way we prevent, treat, and even reverse hair loss,\" stated RepliCel President and CEO, R. Lee Buckler.\n\nSafetyThe five-year trial data set has confirmed the complete safety profile of a high-dose of dermal sheath cup cells (DSCC) for patients with pattern baldness due to androgenetic alopecia.\n\nThese DSCC form the basis for the Company's RCH-01 product. The long-term safety of DSCC injections was demonstrated through multiple physician, patient and independent measures of local and systemic tolerance including evaluation of adverse events with respect to causality, incidence, severity and seriousness. No serious adverse events were reported over the entire 60.5-month follow-up period of the trial. Local injection tolerance was confirmed with only a few minor scalp irritations reported around injection...